Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Ovarian cancer
Phase 2 atorvastatin HMG‑CoA reductase inhibitor immunometabolism add‑on in HGSOC
This University of Colorado Denver–sponsored Phase 2, randomized “window/add-on” study asks whether adding daily atorvastatin (a small‑molecule HMG‑CoA reductase inhibitor that alters cholesterol/mevalonate…
NCT07815704 Exploratory - New trial
Uterine (endometrial) cancer
Early Phase 1 tirzepatide dual GIP/GLP-1 receptor agonist + LNG-IUD progestin in EIN/grade 1 endometrioid EC
This single-arm, window-of-opportunity pilot at Milton S. Hershey Medical Center evaluates feasibility, safety, and preliminary efficacy of adding tirzepatide (Eli Lilly’s dual GIP and GLP-1 receptor agonist that…
NCT07812636 Exploratory - New trial
Uterine (endometrial) cancer
Phase 2 semaglutide GLP-1 receptor agonist + LNG-IUD progestin for fertility-sparing endometrial neoplasia
This Phase 2, single-arm conservative-management study tests whether combining a levonorgestrel-releasing IUD (local progestin that activates the progesterone receptor in the endometrium), semaglutide 2.4 mg (Novo…
NCT07820358 Exploratory - New trial Spotlight
Colorectal cancer
Phase 2 VVD-133214 WRN helicase covalent inhibitor + pembrolizumab (PD-1 antibody) in MSI/dMMR CRC
This randomized, open-label Phase 2 study tests whether adding VVD-133214 (RO7589831)—a first-in-class, covalent allosteric inhibitor of Werner helicase (WRN)—can improve outcomes versus pembrolizumab alone in…
NCT07811193 Exploratory - New trial
Colorectal cancer
Phase 2 porustobart CTLA-4 antibody + pembrolizumab PD-1 antibody in resectable MSS colon cancer
This Phase 2, open-label, multicenter, randomized neoadjuvant trial tests whether adding porustobart (a CTLA-4–blocking monoclonal antibody) to pembrolizumab (a PD-1–blocking monoclonal antibody from Merck/MSD) can…
NCT07808151 Exploratory - New trial
Stomach and esophageal cancer
Phase 1b/2 intratumoral 2141-V11 CD40 agonist added to ongoing first-line PD-1 therapy in gastroesophageal adenocarcinoma
Memorial Sloan Kettering Cancer Center is running this Phase 1b/2, open-label study testing intratumoral 2141-V11, a CD40 agonist antibody, added to ongoing anti–PD-1 therapy with or without 5-FU in advanced…
NCT07818018 Exploratory - New trial
Sarcoma and GIST
Phase 2 LX-101 IGF-1R–targeted methotrexate conjugate in R/R Ewing sarcoma/DSRCT
MD Anderson’s RAPID platform is an open-label, Bayesian, multi-center Phase 2 study designed to quickly screen “promising drugs” and combinations for adolescent and young adult patients with relapsed/refractory Ewing…
NCT07781891 Exploratory - New trial
Multiple solid tumors
Phase 1b SX-682 CXCR1/2 chemokine-receptor inhibitor plus proton CSI for leptomeningeal metastases
Memorial Sloan Kettering Cancer Center is running a Phase 1b, open-label study testing SX-682 (a small-molecule CXCR1/CXCR2 inhibitor that blocks IL-8–axis neutrophil/MDSC trafficking and related tumor-promoting…
NCT07814352 Exploratory - New trial
Multiple solid tumors
Phase 1 AWT020 anti–PD-1–IL-2 fusion protein (checkpoint blockade + cytokine agonist)
This open-label Phase 1 study is determining the maximum tolerated dose and/or recommended Phase 2 dose of AWT020 given as intravenous monotherapy, while also characterizing safety, pharmacokinetics, immunogenicity,…
NCT07822919 Exploratory - New trial
Multiple solid tumors
Phase 1/2 PM54 oncogenic transcription inhibitor + irinotecan/doxorubicin
PharmaMar’s Phase 1/2 open-label, non-randomized master combination study tests PM54, an ecteinascidin-family transcription inhibitor that binds DNA and disrupts oncogenic transcription through RNA polymerase II…
NCT07839819 Exploratory - Trial result
Breast cancer
Pembrolizumab (PD-1) + Neoadjuvant Chemo Cuts Recurrence and Death in Asian Early TNBC Subgroup
Pembrolizumab is an anti–PD-1 checkpoint inhibitor given perioperatively with standard neoadjuvant chemotherapy (taxane + carboplatin → anthracycline/cyclophosphamide) and then continued as adjuvant monotherapy; this…
NCT03036488 - Trial result
Multiple myeloma
Daratumumab (anti-CD38) cuts progression risk in Japanese high-risk SMM vs monitoring (AQUILA)
Daratumumab is an anti-CD38 monoclonal antibody given as monotherapy; in this exploratory post hoc Japanese subgroup of the Phase 3 AQUILA trial (NCT03301220), patients with high-risk smoldering multiple myeloma…
NCT03301220 - Trial result Spotlight
Non-small cell lung cancer
Savolitinib (MET TKI) + osimertinib boosts ORR to 49% when MET is truly “high” (IHC3+/≥90% and/or FISH10+)
Savolitinib is an oral, selective MET tyrosine kinase inhibitor being combined with osimertinib (3rd-gen EGFR TKI) to overcome MET-driven resistance after first-line osimertinib in EGFR-mutated advanced NSCLC in the…
NCT03778229 - Trial result
Colorectal cancer
PEGASUS ctDNA MRD assay guides adjuvant CAPOX→FOLFIRI escalation but misses relapse-free feasibility target in resected MSS colon cancer
PEGASUS (Phase 2, multicenter, single-arm; NCT04259944) tested a postoperative circulating tumor DNA (ctDNA) minimal residual disease (MRD) strategy in resected microsatellite-stable T4N0 (high-risk stage II) and…
NCT04259944 - Trial result Spotlight
Head and neck cancer
PDS0101 (HPV16-targeted immunotherapy) + pembrolizumab drives 34% ORR and 39.3-mo mOS in 1L HPV16+ R/M HNSCC
PDS0101 is a therapeutic HPV16-targeted immunotherapy designed to generate HPV16-specific T-cell responses, here combined with the PD-1 inhibitor pembrolizumab in VERSATILE-002, a Phase 2 open-label, multicenter,…
NCT04260126 - Trial result Spotlight
Acute lymphoblastic leukemia
Blinatumomab (CD19xCD3 BiTE) Replaces 2 Chemo Blocks and Improves 4-year EFS in Pediatric High-Risk B-ALL
Blinatumomab (Blincyto), a CD19xCD3 bispecific T-cell engager that redirects T cells to kill CD19+ B-lineage blasts, was tested in the randomized Phase 3 AIEOP-BFM ALL 2017 study (EudraCT 2016-001935-12; NCT03643276)…
NCT03643276 - Trial result
Colorectal cancer
Adjuvant Chemo Shows No Clear Added Benefit After FOLFIRINOX-Based TNT in Pooled LARC Analysis
A pooled post-hoc analysis of two French randomized trials (GRECCAR 4; NCT01333709 and PRODIGE 23; NCT01804790) evaluated whether postoperative adjuvant chemotherapy (typically fluoropyrimidine/oxaliplatin-based)…
NCT01333709 - Trial result
Lymphoma
Mosunetuzumab (CD20xCD3 bispecific) + response-adapted polatuzumab vedotin (CD79b ADC) drives 86% PET-CR and 89% 2y PFS in untreated indolent NHL
Mosunetuzumab is an IV CD20xCD3 T-cell–engaging bispecific antibody; polatuzumab vedotin is a CD79b-directed antibody–drug conjugate, and obinutuzumab is a type II anti-CD20 mAb. In this single-arm, response-adapted…
- New trial Spotlight
Prostate cancer
Phase 1 FH-STEAP1 IL-18 CAR T tests STEAP1-targeted CAR-T armored with IL-18
Fred Hutchinson Cancer Center is running a first-in-human Phase 1 dose-escalation/expansion study of FH-STEAP1 IL-18 CAR T cells, an autologous anti-STEAP1 CAR-T therapy engineered to secrete IL-18 (a…
NCT07803653 First-in-human - New trial
Prostate cancer
Phase 2 ADT (GnRH antagonist/agonist) + ultra-hypofractionated SBRT in ARTERA-low high-risk prostate cancer
NYU Langone Health is running this single-arm, open-label Phase 2 trial testing whether short-course androgen deprivation therapy (ADT) for 6 months can be paired with dose-escalated radiotherapy…
NCT07801664 Exploratory - New trial
Prostate cancer
Phase 1/2 onabotulinumtoxinA (BOTOX) neuromuscular blocker (SNARE-mediated ACh release inhibitor) in high-risk prostate cancer
This Phase 1/2 pilot from Houston Methodist (The Methodist Hospital Research Institute) randomizes 30 men 1:1 in a single-blind, placebo-controlled design to a one-time intraprostatic onabotulinumtoxinA injection (50…
NCT07796490 Exploratory - New trial Spotlight
Colorectal cancer
Phase 2 trastuzumab rezetecan (SHR-A1811) HER2-directed topoisomerase I inhibitor ADC in 1L mCRC
HORIZON-CRC221 is a global, multicenter, randomized, dose-optimization Phase 2 study testing two dose levels of trastuzumab rezetecan (SHR-A1811)—a HER2-targeted monoclonal antibody–drug conjugate delivering a…
NCT07796763 Exploratory - New trial Spotlight
Lymphoma
Phase 2 BOSon tests zanubrutinib + obinutuzumab + sonrotoclax in frontline MCL
Memorial Sloan Kettering Cancer Center is running this Phase 2 study of a chemotherapy-free, MRD-guided frontline regimen for transplant-ineligible patients with stage II–IV mantle cell lymphoma. Treatment combines…
NCT07799220 Exploratory - New trial
Pancreatic cancer
Phase 1b/2 PRISM‑TAMP tests arterial gemcitabine chemotherapy microperfusion
University of Vermont is running this Phase 1b/2, single-arm, open-label study in borderline resectable pancreatic ductal adenocarcinoma to see whether adding trans-arterial microperfusion (TAMP) delivery of…
NCT07477418 Exploratory - New trial
Breast cancer
Phase 2 TheraBionic P1 amplitude‑modulated RF electromagnetic field (tumor‑frequency EMF) device in HR+ breast cancer.
This Phase 2, open-label, single-arm study tests the TheraBionic P1 mouth device as a self-administered, non-drug intervention for locally advanced/unresectable or metastatic hormone receptor–positive (ER/PR >1% in…
NCT07227831 Exploratory - New trial
Small cell lung cancer
Phase 2 sacituzumab govitecan TROP2-directed SN-38 ADC + PD-L1 blockade maintenance in ES-SCLC
This Phase 2, open-label maintenance study tests whether adding sacituzumab govitecan (SG)—a TROP2-targeted monoclonal antibody–drug conjugate delivering the topoisomerase I inhibitor SN-38 (Gilead Sciences’…
NCT07339059 Exploratory - New trial
Lymphoma
Phase 2 epcoritamab CD3×CD20 bispecific T‑cell engager vs watchful waiting in low‑burden FL.
This randomized Phase 2 study at MD Anderson Cancer Center tests whether starting epcoritamab earlier can delay the need for conventional lymphoma therapy in previously untreated, low tumor burden follicular lymphoma…
NCT07783594 Exploratory - Trial result
Non-small cell lung cancer
Osimertinib (EGFR TKI) Sustains 8-Year OS Benefit After Resected EGFR-Mutant NSCLC
Osimertinib is a 3rd-generation, CNS-penetrant EGFR tyrosine kinase inhibitor given for 3 years after surgery for EGFR exon 19 deletion or L858R-mutant NSCLC. In this long-term update of the Phase 3 ADAURA trial…
- Trial result
Breast cancer
A tumor-informed ctDNA MRD assay flags post-surgery recurrence risk in early TNBC (HR 30.3)
This NSABP B-59/GBG-96-GeparDouze prospective ctDNA substudy used whole-exome sequencing of each patient’s primary tumor to build a bespoke “tumor-informed” circulating tumor DNA (ctDNA) MRD assay, testing serial…
- Trial result Spotlight
Acute lymphoblastic leukemia
Everolimus (mTOR inhibitor) + NECTAR salvage delivers 75% ORR in pediatric/AYA R/R T-ALL/T-LL
Everolimus is an oral mTORC1 inhibitor combined here with NECTAR chemotherapy (nelarabine + cyclophosphamide + etoposide) in the multisite ENCERT Phase 1 dose-escalation study in children/young adults with…
NCT03328104
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.